Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22916040 | 0.79 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL13483784 | 0.79 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL13483787 | 0.79 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL15534390 | 0.79 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL14828382 | 0.79 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL20011654 | 0.79 | — | — | |
| SCHEMBL12536222 | 0.78 | KCNH2 (0.31) | KCNH2SSTR4HRH4HRH3HRH2 | |
| SCHEMBL12536215 | 0.78 | KCNH2 (0.31) | KCNH2SSTR4HRH4HRH3HRH2 | |
| SCHEMBL12536216 | 0.78 | GBA1 (0.33) | KCNH2HRH4HRH3HRH2 | |
| SCHEMBL12536225 | 0.78 | GBA1 (0.33) | KCNH2HRH4HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |